Company Filing History:
Years Active: 1994-1998
Title: Innovations of Robert H Gundel in Asthma Treatment
Introduction
Robert H Gundel is a notable inventor based in Pawling, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of asthma. With a total of 2 patents, Gundel's work focuses on the use of intercellular adhesion molecules and their binding ligands.
Latest Patents
Gundel's latest patents include innovative methods for utilizing intercellular adhesion molecule-1 (ICAM-1) and fragments thereof, as well as anti-CD18 antibodies in the treatment of asthma. One of his inventions relates to the use of these molecules to reduce the severity of asthma symptoms. Specifically, he discloses that administering anti-adhesion antibodies, such as anti-ICAM-1 or anti-CD18 family member antibodies, can decrease the hyperresponsive reactions associated with asthma.
Career Highlights
Robert H Gundel is currently employed at Boehringer Ingelheim Pharmaceuticals, Inc., where he continues to advance research in respiratory diseases. His work has been instrumental in developing new therapeutic approaches for asthma patients.
Collaborations
Gundel has collaborated with several professionals in his field, including Craig D Wegner and Robert Rothlein. These partnerships have contributed to the success of his research and innovations.
Conclusion
Robert H Gundel's contributions to asthma treatment through his patents and research at Boehringer Ingelheim Pharmaceuticals, Inc. highlight his dedication to improving patient outcomes. His innovative approaches continue to pave the way for advancements in medical science.